Tue, May 13, 8:18 PM (34 days ago)
**RANI THERAPEUTICS HOLDINGS, INC. (RANI)** **Q1 2025 Financial Summary** **Financial Health and Performance:** - **Revenue:** $172,000 from contract revenue, up from $0 in Q1 2024. - **Operating Expenses:** $12.2 million, down 13.2% from $14.0 million in Q1 2024. - **R&D Expenses:** $6.6 million, down 13.4% from $7.6 million in Q1 2024. - **G&A Expenses:** $5.6 million, down 12.9% from $6.4 million in Q1 2024. - **Net Loss:** $12.7 million, down 13.8% from $14.8 million in Q1 2024. - **Cash Flow:** Negative $8.1 million from operations, improved from negative $9.4 million in Q1 2024. - **Cash Position:** $15.9 million in cash, cash equivalents, and marketable securities as of March 31, 2025. **Profit Margins:** - **Operating Margin:** -100% (Loss from operations of $12.0 million on $0 revenue). - **Net Margin:** -733% (Net loss of $12.7 million on $172,000 revenue). **Earnings Changes:** - **EPS:** -$0.22, improved from -$0.29 in Q1 2024. **Trends and Uncertainties:** - **Going Concern:** Substantial doubt about the ability to continue as a going concern for a period of one year after the date that the financial statements for the three months ended March 31, 2025, are issued. - **Funding:** Needs to raise substantial additional funds to complete development, clinical trials, and commercialization. - **Market Risk:** Subject to market risks, including changes in interest rates, foreign exchange rates, and equity prices. - **Operational Risks:** Dependence on third-party suppliers, regulatory approvals, and intellectual property protection. **Future Operations Impact:** - **Clinical Trials:** Plans to initiate clinical testing of the RaniPill HC in mid-2025. - **Partnerships:** Actively pursuing partnering the technology with third-party biopharmaceutical companies. - **Manufacturing:** Investing in automated manufacturing production lines for the RaniPill capsule. **Stock Performance (as of May 12, 2025):** - **Shares Outstanding:** 33,570,253 shares of Class A common stock. - **Market Risk:** Subject to market risks, including changes in interest rates, foreign exchange rates, and equity prices. **Forward-Looking Statements:** - The company's actual results could differ materially from those discussed in or implied by these forward-looking statements due to various risks and uncertainties.